Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

키워드

참고문헌 (95)

1. Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virusendemic population", Hepatology, 66, pp.1454~1463 (2017)
2. Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
3. Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the Global Burden of Disease Study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
4. Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease", Gut, 63, pp.1943~1950 (2014)
5. Kanwal F, "Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents", Gastroenterology, 153, pp.996~1005 (2017)
6. Simon TG, "Association of aspirin with hepatocellular carcinoma and liver-related mortality", N Engl J Med, 382, pp.1018~1028 (2020)
7. Zhong GC, "Meta-analysis of studies using statins as a reducer for primary liver cancer risk", Sci Rep, 6, pp.26256~ (2016)
8. Wong YJ, "Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients : a systematic review and meta-analysis", J Clin Gastroenterol, 55, pp.615~623 (2021)
9. Singh S, "Statins are associated with a reduced risk of hepatocellular cancer : a systematic review and meta-analysis", Gastroenterology, 144, pp.323~332 (2013)
10. Rzouq FS, "Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians", Am J Med Sci, 340, pp.89~93 (2010)
11. Blais P, "Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia", Dig Dis Sci, 61, pp.1714~1720 (2016)
12. Cai A, "Rho-GTPase and atherosclerosis : pleiotropic effects of statins", J Am Heart Assoc, 4, pp.e002113~ (2015)
13. Schierwagen R, "Statins improve NASH via inhibition of RhoA and Ras", Am J Physiol Gastrointest Liver Physiol, 311, pp.G724~G733 (2016)
14. Arnaud C, "Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes : new evidence for direct antiinflammatory effects of statins", Arterioscler Thromb Vasc Biol, 25, pp.1231~1236 (2005)
15. Chong LW, "Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells", BMC Gastroenterol, 15, pp.22~ (2015)
16. Uschner FE, "Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension", Sci Rep, 5, pp.14573~ (2015)
17. Marrone G, "The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins", J Hepatol, 58, pp.98~103 (2013)
18. Jha P, "KLF2 in regulation of NF-κB-mediated immune cell function and inflammation", Int J Mol Sci, 18, pp.2383~ (2017)
19. Janicko M, "Pleiotropic effects of statins in the diseases of the liver", World J Gastroenterol, 22, pp.6201~6213 (2016)
20. Kim G, "Prevention of hepatocellular carcinoma by statins : clinical evidence and plausible mechanisms", Semin Liver Dis, 39, pp.141~152 (2019)
21. Wang ST, "Simvastatin-induced cell cycle arrest through inhibition of STAT3", SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells, 2017, pp.8, e2626~
22. Relja B, "Simvastatin inhibits cell growth and induces apoptosis and G0", G1 cell cycle arrest in hepatic cancer cells, 2010, pp.26, 735~741
23. Cao Z, "MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMGCoA reductase", Cancer Res, 71, pp.2286~2297 (2011)
24. Dulak J, "Anti-angiogenic and anti-inflammatory effects of statins : relevance to anti-cancer therapy", Curr Cancer Drug Targets, 5, pp.579~594 (2005)
25. Friis S, "Cancer risk among statin users : a population-based cohort study", Int J Cancer, 114, pp.643~647 (2005)
26. Cholesterol Treatment Trialists’(CTT)Collaboration, "Lack of effect of lowering LDL cholesterol on cancer : meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy", PLoS One, 7, pp.e29849~ (2012)
27. Chiu HF, "Statin use and the risk of liver cancer : a population-based case–control study", Am J Gastroenterol, 106, pp.894~898 (2011)
28. McGlynn KA, "Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink", J Natl Cancer Inst (2015)
29. Tran KT, "Statin use and risk of liver cancer : evidence from two population-based studies", Int J Cancer, 146, pp.1250~1260 (2020)
30. Björkhem-Bergman L, "Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden", Pharmacoepidemiol Drug Saf, 23, pp.1101~1106 (2014)
31. Chang Y, "Can statin treatment reduce the risk of hepatocellular carcinoma? A systematic review and meta-analysis", Technol Cancer Res Treat, 19, pp.1533033820934881~ (2020)
32. Tsan YT, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection", J Clin Oncol, 30, pp.623~630 (2012)
33. Tsan YT, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis c virus infection", J Clin Oncol, 31, pp.1514~1521 (2013)
34. Goh MJ, "Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology, 71, pp.2023~2032 (2020)
35. Hsiang JC, "Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population : a propensity score landmark analysis", J Hepatol, 63, pp.1190~1197 (2015)
36. Butt AA, "Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons : results from ERCHIVES", Hepatology, 62, pp.365~374 (2015)
37. Pinyopornpanish K, "Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis", Am J Gastroenterol, 116, pp.2258~2269 (2021)
38. Islam MM, "Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies", Cancers(Basel), 12, pp.671~ (2020)
39. Egom EE, "Biochemistry of statins", Adv Clin Chem, 73, pp.127~168 (2016)
40. Bader T, "Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro", Antiviral Res, 86, pp.241~245 (2010)
41. Menter DG, "Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites", PLoS One, 6, pp.e28813~ (2011)
42. Spampanato C, "Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and downregulation of BCL-2 gene expression", Int J Oncol, 40, pp.935~941 (2012)
43. Kato S, "Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase", J Cell Mol Med, 14, pp.1180~1193 (2010)
44. Simon TG, "Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis : results from a nationwide swedish population", Ann Intern Med, 171, pp.318~327 (2019)
45. Li X, "Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection : a meta-analysis", BMC Gastroenterol, 20, pp.98~ (2020)
46. Facciorusso A, "Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis", Cancers(Basel), 12, pp.874~ (2020)
47. Yi C, "Statins intake and risk of liver cancer: a dose-response meta analysis of prospective cohort studie", Medicine(Baltimore), 96, pp.e7435~ (2017)
48. Weis M, "Statins have biphasic effects on angiogenesis", Circulation, 105, pp.739~745 (2002)
49. Björnsson E, "Hepatotoxicity associated with statins : reports of idiosyncratic liver injury postmarketing", J Hepatol, 56, pp.374~380 (2012)
50. Ward NC, "Statin toxicity", Circ Res, 124, pp.328~350 (2019)
51. Study of the Effectiveness of Additional Reductions in Cholesterol, "Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction : a double-blind randomised trial", Lancet, 376, pp.1658~1669 (2010)
52. Pose E, "Statins : old drugs as new therapy for liver diseases?", J Hepatol, 70, pp.194~202 (2019)
53. Kaplan DE, "Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis", Gastroenterology, 156, pp.1693~1706 (2019)
54. Abraldes JG, "Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis", Gastroenterology, 150, pp.1160~1170 (2016)
55. Bays H, "The National Lipid Association’s Statin Safety Task Force. An assessment by the statin liver safety task force: 2014 update", J Clin Lipidol, 8, pp.S47~S57 (2014)
56. Jeong GH, "Effect of statin on cancer incidence : an umbrella systematic review and meta-analysis", J Clin Med, 8, pp.819~ (2019)
57. Shi M, "Statin use and risk of liver cancer : an update meta-analysis", BMJ Open, 4, pp.e005399~ (2014)
58. Lichtenberger LM, "Are platelets the primary target of aspirin’s remarkable anticancer activity?", Cancer Res, 79, pp.3820~3823 (2019)
59. Guidotti LG, "Immunosurveillance of the liver by intravascular effector CD8(+)T cells", Cell, 161, pp.486~500 (2015)
60. Sitia G, "Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B", Proc Natl Acad Sci U S A, 109, pp.E2165~E2172 (2012)
61. Wong RSY, "Role of nonsteroidal anti-inflammatory drugs(NSAIDs)in cancer prevention and cancer promotion", Adv Pharmacol Sci, 2019, pp.3418975~ (2019)
62. Leng J, "Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation : evidence for Akt inhibition in celecoxibinduced apoptosis", Hepatology, 38, pp.756~768 (2003)
63. Rothwell PM, "Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death : analysis of the time course of risks and benefits in 51 randomised controlled trials", Lancet, 379, pp.1602~1612 (2012)
64. Sahasrabuddhe VV, "Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma", J Natl Cancer Inst, 104, pp.1808~1814 (2012)
65. Petrick JL, "NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project", Cancer Prev Res(Phila), 8, pp.1156~1162 (2015)
66. Hwang IC, "Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults", Sci Rep, 8, pp.4968~ (2018)
67. Tsoi KKF, "Long-term use of lowdose aspirin for cancer prevention : a 10-year population cohort study in Hong Kong", Int J Cancer, 145, pp.267~273 (2019)
68. Yang B, "Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research Datalink", Cancer Epidemiol, 43, pp.105~111 (2016)
69. Lee M, "Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment", Hepatology, 66, pp.1556~1569 (2017)
70. Lee TY, "Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B", JAMA Intern Med, 179, pp.633~640 (2019)
71. Hui VW, "Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis b receiving oral nucleos(t)ide analog", Clin Transl Gastroenterol, 12, pp.e00324~ (2021)
72. Liao YH, "Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers : a nationwide cohort study", BMC Gastroenterol, 20, pp.6~ (2020)
73. Lee TY, "Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis C virus infection", Clin Gastroenterol Hepatol, 18, pp.2784~2792 (2020)
74. Tan RZH, "Systematic review with meta-analysis : the effects of non-steroidal antiinflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma", Aliment Pharmacol Ther, 54, pp.356~367 (2021)
75. Wang S, "Association of aspirin therapy with risk of hepatocellular carcinoma : a systematic review and dose-response analysis of cohort studies with 2. 5 million participants", Pharmacol Res, 151, pp.104585~ (2020)
76. Shin S, "Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis", Medicine(Baltimore), 99, pp.e19008~ (2020)
77. Du ZQ, "Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy : a retrospective single-center study", World J Gastroenterol, 25, pp.3798~3807 (2019)
78. Li X, "Aspirin use and the incidence of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis of cohort studies", Front Med(Lausanne), 7, pp.569759~ (2021)
79. Memel ZN, "Aspirin use is associated with a reduced incidence of hepatocellular carcinoma : a systematic review and metaanalysis", Hepatol Commun, 5, pp.133~143 (2021)
80. Zheng SL, "Association of aspirin use for primary prevention with cardiovascular events and bleeding events : a systematic review and meta-analysis", JAMA, 321, pp.277~287 (2019)
81. Planas R, "Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites", Gastroenterology, 84, pp.247~252 (1983)
82. Mak LY, "Proton pump inhibitors in chronic liver disease : accomplice or bystander?", Hepatol Int, 14, pp.299~301 (2020)
83. "The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document)"[URL]
84. El-Serag HB, "Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes", Gastroenterology, 136, pp.1601~1608 (2009)
85. Marelli C, "Statins and risk of cancer : a retrospective cohort analysis of 45, 857 matched pairs from an electronic medical records database of 11 million adult Americans", J Am Coll Cardiol, 58, pp.530~537 (2011)
86. Lai SW, "Statin use and risk of hepatocellular carcinoma", Eur J Epidemiol, 28, pp.485~492 (2013)
87. McGlynn KA, "Statin use and risk of hepatocellular carcinoma in a U. S. population", Cancer Epidemiol, 38, pp.523~527 (2014)
88. Kim G, "Statin use and the risk of hepatocellular carcinoma in patients at high risk : a nationwide nested case-control study", J Hepatol, 68, pp.476~484 (2018)
89. Chen CI, "Cancer risk in HBV patients with statin and metformin use: a population-based cohort study", Medicine(Baltimore), 94, pp.e462~ (2015)
90. Simon TG, "Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus : results from ERCHIVES", Hepatology, 64, pp.47~57 (2016)
91. Mohanty A, "Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis", Gastroenterology, 150, pp.430~440 (2016)
92. German MN, "Statin use is protective against hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : a case-control study", J Clin Gastroenterol, 54, pp.733~740 (2020)
93. Simon TG, "Association between aspirin use and risk of hepatocellular carcinoma", JAMA Oncol, 4, pp.1683~1690 (2018)
94. Shen Y, "Risk factors for hepatocellular carcinoma(HCC)in the northeast of the United States : results of a case-control study", Cancer Causes Control, 31, pp.321~332 (2020)
95. Lee TY, "The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease", Int J Cancer, 141, pp.1307~1314 (2017)

관련 논문AI추천